Q14160 (SCRIB_HUMAN) Reviewed, UniProtKB/Swiss-Prot
Last modified
May 1, 2013.
Version 134.
History...
Names·Attributes·General annotation·Ontologies·Interactions·Alt products·Sequence annotation·Sequences·References·Cross-refs·Entry info·DocumentsCustomize order
Names·Attributes·General annotation·Ontologies·Interactions·Alt products·Sequence annotation·Sequences·References·Cross-refs·Entry info·DocumentsCustomize orderNames and origin
| Protein names | Recommended name: Protein scribble homolog Short name=Scribble Short name=hScrib Alternative name(s): Protein LAP4 | ||||
| Gene names |
| ||||
| Organism | Homo sapiens (Human) [Reference proteome] | ||||
| Taxonomic identifier | 9606 [NCBI] | ||||
| Taxonomic lineage | Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo![]() |
Protein attributes
| Sequence length | 1630 AA. |
| Sequence status | Complete. |
| Protein existence | Evidence at protein level |
General annotation (Comments)
| Function | Scaffold protein involved in different aspects of polarized cells differentiation regulating epithelial and neuronal morphogenesis. Most probably functions in the establishment of apico-basal cell polarity. May function in cell proliferation regulating progression from G1 to S phase and as a positive regulator of apoptosis for instance during acinar morphogenesis of the mammary epithelium. May also function in cell migration and adhesion and hence regulate cell invasion through MAPK signaling. May play a role in exocytosis and in the targeting synaptic vesicles to synapses. Functions as an activator of Rac GTPase activity. Ref.11 Ref.12 Ref.15 Ref.16 Ref.19 Ref.20 Ref.22 |
| Subunit structure | Interacts (via PDZ domains) with VANGL2. Interacts with CTNNB1 and MAPK12 By similarity. Interacts with UBE3A and HPV E6. Interacts with PAK1 and PAK2. Interacts with ARHGEF7 and GIT1; interacts directly with ARHGEF7. Interacts (via PDZ domains) with LPP and TRIP6; the interaction is direct. Interacts (via PDZ domains) with TJP2. Interacts (via PDZ domains) with APC; may mediate APC targeting to adherens junctions of epithelial cells. Interacts (via PDZ domains) with TSHR; regulates TSHR trafficking and function. Interacts with MCC. Interacts (via fourth PDZ domain) with tick-borne encephalitis virus NS5 protein; this interaction inhibits SCRIB and downstream STAT1 phosphorylation, thereby preventing activation of JAK-STAT signaling pathway. Ref.1 Ref.9 Ref.11 Ref.12 Ref.13 Ref.14 Ref.18 Ref.20 Ref.23 Ref.25 |
| Subcellular location | Cell membrane; Peripheral membrane protein. Cell junction › adherens junction. Cytoplasm. Note: Targeting to cell-cell junctions which is CDH1-dependent is required for the pro-apoptotic activity. Localizes to neuronal post- and pre-synaptic regions. Ref.1 Ref.2 Ref.9 Ref.11 Ref.16 Ref.18 Ref.19 |
| Tissue specificity | Expressed in kidney, skeletal muscles, liver, lung, breast, intestine, placenta and skin mainly in epithelial cells (at protein level). Ref.2 |
| Post-translational modification | Ubiquitinated; targeted for UBE3A-dependent multiubiquitination in the presence of high-risk HPV E6 proteins and degraded. Ref.9 |
| Involvement in disease | Neural tube defects (NTD) [MIM:182940]: Congenital malformations of the central nervous system and adjacent structures related to defective neural tube closure during the first trimester of pregnancy. Failure of neural tube closure can occur at any level of the embryonic axis. Common NTD forms include anencephaly, myelomeningocele and spina bifida, which result from the failure of fusion in the cranial and spinal region of the neural tube. NTDs have a multifactorial etiology encompassing both genetic and environmental components. |
| Sequence similarities | Belongs to the LAP (LRR and PDZ) protein family. Contains 16 LRR (leucine-rich) repeats. Contains 4 PDZ (DHR) domains. |
Ontologies
Binary interactions
With | Entry | #Exp. | IntAct | Notes |
|---|---|---|---|---|
| MAPK3 | P27361 | 2 | EBI-357345,EBI-73995 |
Alternative products
| This entry describes 3 isoforms produced by alternative splicing. [Align] [Select] | ||||||
| Isoform 1 (identifier: Q14160-1) This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry. | ||||||
| Isoform 2 (identifier: Q14160-2) Also known as: Variant N1; The sequence of this isoform differs from the canonical sequence as follows: 1-81: Missing. | ||||||
| Note: No experimental confirmation available. | ||||||
| Isoform 3 (identifier: Q14160-3) The sequence of this isoform differs from the canonical sequence as follows: 1565-1565: L → LPLSGKKFDYRAFAALPSSRPVYDIQ |
Sequence annotation (Features)
| Feature key | Position(s) | Length | Description | Graphical view | Feature identifier | ||||||||||||||||||||||||||||||||||||||||||||||||||
Molecule processing | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chain | 1 – 1630 | 1630 | Protein scribble homolog | PRO_0000188303 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Regions | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Repeat | 37 – 58 | 22 | LRR 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Repeat | 60 – 81 | 22 | LRR 2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Repeat | 83 – 104 | 22 | LRR 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Repeat | 106 – 127 | 22 | LRR 4 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Repeat | 129 – 150 | 22 | LRR 5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Repeat | 152 – 174 | 23 | LRR 6 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Repeat | 175 – 197 | 23 | LRR 7 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Repeat | 198 – 219 | 22 | LRR 8 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Repeat | 221 – 243 | 23 | LRR 9 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Repeat | 244 – 265 | 22 | LRR 10 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Repeat | 267 – 288 | 22 | LRR 11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Repeat | 290 – 312 | 23 | LRR 12 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Repeat | 313 – 334 | 22 | LRR 13 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Repeat | 336 – 357 | 22 | LRR 14 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Repeat | 359 – 381 | 23 | LRR 15 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Repeat | 382 – 402 | 21 | LRR 16 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Domain | 728 – 815 | 88 | PDZ 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Domain | 862 – 950 | 89 | PDZ 2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Domain | 1004 – 1093 | 90 | PDZ 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Domain | 1100 – 1194 | 95 | PDZ 4 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Region | 1 – 818 | 818 | Sufficient for targeting to adherens junction and to inhibit cell proliferation | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Region | 717 – 1229 | 513 | Interaction with ARHGEF7 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Coiled coil | 458 – 474 | 17 | Potential | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Coiled coil | 656 – 701 | 46 | Potential | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Coiled coil | 1379 – 1419 | 41 | Potential | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Compositional bias | 660 – 695 | 36 | Glu-rich | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Compositional bias | 1296 – 1349 | 54 | Pro-rich | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Amino acid modifications | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 688 | 1 | Phosphoserine Ref.30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 689 | 1 | Phosphothreonine Ref.30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 826 | 1 | Phosphothreonine Ref.24 Ref.27 Ref.28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 835 | 1 | Phosphoserine Ref.28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 853 | 1 | Phosphoserine Ref.17 Ref.28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 939 | 1 | Phosphoserine Ref.24 Ref.28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 1140 | 1 | Phosphoserine Ref.28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 1220 | 1 | Phosphoserine Ref.10 Ref.27 Ref.28 Ref.30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 1223 | 1 | Phosphoserine Ref.24 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 1232 | 1 | Phosphoserine Ref.24 Ref.28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 1306 | 1 | Phosphoserine Ref.17 Ref.24 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 1309 | 1 | Phosphoserine Ref.17 Ref.24 Ref.30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 1342 | 1 | Phosphothreonine Ref.24 Ref.27 Ref.28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 1348 | 1 | Phosphoserine Ref.24 Ref.26 Ref.27 Ref.28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 1378 | 1 | Phosphoserine Ref.17 Ref.28 Ref.30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 1437 | 1 | Phosphoserine Ref.24 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 1448 | 1 | Phosphoserine Ref.26 Ref.28 Ref.30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 1475 | 1 | Phosphoserine Ref.21 Ref.27 Ref.28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 1486 | 1 | Phosphoserine Ref.28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 1547 | 1 | Phosphoserine Ref.24 Ref.27 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 1566 | 1 | Phosphoserine Ref.21 Ref.24 Ref.27 Ref.28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Natural variations | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Alternative sequence | 1 – 81 | 81 | Missing in isoform 2. | VSP_010906 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Alternative sequence | 1565 | 1 | L → LPLSGKKFDYRAFAALPSSR PVYDIQ in isoform 3. | VSP_010908 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Natural variant | 422 | 1 | P → L. Ref.1 Ref.2 Ref.3 Ref.4 Corresponds to variant rs6558394 [ dbSNP | Ensembl ]. | VAR_019429 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Natural variant | 454 | 1 | P → S in NTD; protein interactions not affected by the mutation; shows reduced protein localization to the cell membrane. Ref.32 | VAR_067219 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Natural variant | 1535 | 1 | R → Q in NTD; protein interactions not affected by the mutation; shows reduced protein localization to the cell membrane. Ref.32 | VAR_067220 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Experimental info | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 305 | 1 | P → L: Loss of pro-apoptotic function and of the targeting to cell-cell junctions. Targeted to the cytoplasm. Alters interaction with TJP2. Ref.2 Ref.19 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 738 – 739 | 2 | LG → AE: Alters interaction with LPP. | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 738 | 1 | L → R: Loss of anti-proliferative activity. | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 872 – 873 | 2 | LG → AE: Alters interaction with LPP. | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 1014 – 1015 | 2 | LG → AE: Loss of interaction with LPP and TRIP6. Ref.1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 1111 – 1112 | 2 | LG → AE: Alters interaction with LPP. Ref.1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sequence conflict | 674 | 1 | V → E in AAP88017. Ref.1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sequence conflict | 674 | 1 | V → E in AAL38976. Ref.2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sequence conflict | 674 | 1 | V → E in AAP88018. Ref.3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sequence conflict | 674 | 1 | V → E in BAA09768. Ref.4 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sequence conflict | 1489 | 1 | E → K in AAL38976. Ref.2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Secondary structure | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Helix Strand Turn | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 726 – 732 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 737 – 744 | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 757 – 763 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 768 – 772 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 779 – 783 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 793 – 801 | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 805 – 812 | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 860 – 865 | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 875 – 877 | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 893 – 896 | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 903 – 906 | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 914 – 920 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 928 – 935 | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 942 – 948 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 1097 – 1099 | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 1101 – 1104 | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 1113 – 1116 | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 1119 – 1122 | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 1135 – 1139 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 1144 – 1148 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 1159 – 1162 | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 1170 – 1177 | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 1181 – 1186 | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Sequences
| ||||||||||||||||||||||||||||||
References
| « Hide 'large scale' references | |
| [1] | "The tumor suppressor Scrib interacts with the zyxin-related protein LPP, which shuttles between cell adhesion sites and the nucleus." Petit M.M.R., Meulemans S.M.P., Alen P., Ayoubi T.A.Y., Jansen E., Van de Ven W.J.M. BMC Cell Biol. 6:1-1(2005) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH LPP, SUBCELLULAR LOCATION, MUTAGENESIS OF 738-LEU--GLY-739; 872-LEU--GLY-873; 1014-LEU--GLY-1015 AND 1111-LEU--GLY-1112, VARIANT LEU-422. |
| [2] | "Junctional recruitment of mammalian Scribble relies on E-cadherin engagement." Navarro C., Nola S., Audebert S., Santoni M.-J., Arsanto J.-P., Ginestier C., Marchetto S., Jacquemier J., Isnardon D., Le Bivic A., Birnbaum D., Borg J.-P. Oncogene 24:4330-4339(2005) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT LEU-422, SUBCELLULAR LOCATION, MUTAGENESIS OF PRO-305, TISSUE SPECIFICITY. |
| [3] | "The human Scrib N1 variant encoded by the SCRIB gene contains 13 leucine-rich repeats and 4 PDZ domains." Petit M.M.R., Alen P., Meulemans S.M.P., Van de Wouwer E., Ayoubi T.A.Y., Van de Ven W.J.M., Jansen E. Submitted (JUL-2008) to the EMBL/GenBank/DDBJ databases Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), VARIANT LEU-422. |
| [4] | "Prediction of the coding sequences of unidentified human genes. IV. The coding sequences of 40 new genes (KIAA0121-KIAA0160) deduced by analysis of cDNA clones from human cell line KG-1." Nagase T., Seki N., Tanaka A., Ishikawa K., Nomura N. DNA Res. 2:167-174(1995) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), VARIANT LEU-422. Tissue: Bone marrow and Brain. |
| [5] | "Construction of expression-ready cDNA clones for KIAA genes: manual curation of 330 KIAA cDNA clones." Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T. DNA Res. 9:99-106(2002) [PubMed] [Europe PMC] [Abstract] Cited for: SEQUENCE REVISION. |
| [6] | Ohara O., Nagase T., Kikuno R., Nomura N. Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases Cited for: SEQUENCE REVISION. |
| [7] | "DNA sequence and analysis of human chromosome 8." Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M., Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S., Asakawa T. Lander E.S.Nature 439:331-335(2006) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. |
| [8] | "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)." The MGC Project Team Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 799-1630 (ISOFORM 1), NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1206-1630 (ISOFORM 3). Tissue: Lung carcinoma and Neuroblastoma. |
| [9] | "Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase." Nakagawa S., Huibregtse J.M. Mol. Cell. Biol. 20:8244-8253(2000) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH UBE3A AND HPV E6, UBIQUITINATION, SUBCELLULAR LOCATION. |
| [10] | "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from human T cells using immobilized metal affinity chromatography and tandem mass spectrometry." Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M., Peters E.C. Anal. Chem. 76:2763-2772(2004) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1220, MASS SPECTROMETRY. Tissue: Leukemic T-cell. |
| [11] | "Mammalian Scribble forms a tight complex with the betaPIX exchange factor." Audebert S., Navarro C., Nourry C., Chasserot-Golaz S., Lecine P., Bellaiche Y., Dupont J.-L., Premont R.T., Sempere C., Strub J.-M., Van Dorsselaer A., Vitale N., Borg J.-P. Curr. Biol. 14:987-995(2004) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION, INTERACTION WITH ARHGEF7 AND GIT1, SUBCELLULAR LOCATION. |
| [12] | "Thyrotropin receptor trafficking relies on the hScrib-betaPIX-GIT1-ARF6 pathway." Lahuna O., Quellari M., Achard C., Nola S., Meduri G., Navarro C., Vitale N., Borg J.-P., Misrahi M. EMBO J. 24:1364-1374(2005) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION, INTERACTION WITH TSHR. |
| [13] | "hScrib interacts with ZO-2 at the cell-cell junctions of epithelial cells." Metais J.-Y., Navarro C., Santoni M.-J., Audebert S., Borg J.-P. FEBS Lett. 579:3725-3730(2005) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH TJP2. |
| [14] | "The tumor suppressor Scrib selectively interacts with specific members of the zyxin family of proteins." Petit M.M.R., Crombez K.R.M.O., Vervenne H.B.V.K., Weyns N., Van de Ven W.J.M. FEBS Lett. 579:5061-5068(2005) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH TRIP6. |
| [15] | "The mammalian Scribble polarity protein regulates epithelial cell adhesion and migration through E-cadherin." Qin Y., Capaldo C., Gumbiner B.M., Macara I.G. J. Cell Biol. 171:1061-1071(2005) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION IN CELL ADHESION. |
| [16] | "Human homolog of Drosophila tumor suppressor Scribble negatively regulates cell-cycle progression from G1 to S phase by localizing at the basolateral membrane in epithelial cells." Nagasaka K., Nakagawa S., Yano T., Takizawa S., Matsumoto Y., Tsuruga T., Nakagawa K., Minaguchi T., Oda K., Hiraike-Wada O., Ooishi H., Yasugi T., Taketani Y. Cancer Sci. 97:1217-1225(2006) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION IN CELL PROLIFERATION, SUBCELLULAR LOCATION. |
| [17] | "Global, in vivo, and site-specific phosphorylation dynamics in signaling networks." Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M. Cell 127:635-648(2006) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-853; SER-1306; SER-1309 AND SER-1378, MASS SPECTROMETRY. Tissue: Cervix carcinoma. |
| [18] | "Human scribble, a novel tumor suppressor identified as a target of high-risk HPV E6 for ubiquitin-mediated degradation, interacts with adenomatous polyposis coli." Takizawa S., Nagasaka K., Nakagawa S., Yano T., Nakagawa K., Yasugi T., Takeuchi T., Kanda T., Huibregtse J.M., Akiyama T., Taketani Y. Genes Cells 11:453-464(2006) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH APC, SUBCELLULAR LOCATION. |
| [19] | "Deregulation of scribble promotes mammary tumorigenesis and reveals a role for cell polarity in carcinoma." Zhan L., Rosenberg A., Bergami K.C., Yu M., Xuan Z., Jaffe A.B., Allred C., Muthuswamy S.K. Cell 135:865-878(2008) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION IN APOPTOSIS, SUBCELLULAR LOCATION, MUTAGENESIS OF PRO-305. |
| [20] | "Scrib regulates PAK activity during the cell migration process." Nola S., Sebbagh M., Marchetto S., Osmani N., Nourry C., Audebert S., Navarro C., Rachel R., Montcouquiol M., Sans N., Etienne-Manneville S., Borg J.-P., Santoni M.-J. Hum. Mol. Genet. 17:3552-3565(2008) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION IN CELL MIGRATION, INTERACTION WITH PAK1 AND PAK2. |
| [21] | "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis." Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III J. Proteome Res. 7:1346-1351(2008) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1475 AND SER-1566, MASS SPECTROMETRY. Tissue: Cervix carcinoma. |
| [22] | "Loss of human Scribble cooperates with H-Ras to promote cell invasion through deregulation of MAPK signalling." Dow L.E., Elsum I.A., King C.L., Kinross K.M., Richardson H.E., Humbert P.O. Oncogene 27:5988-6001(2008) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION. |
| [23] | "Tick-borne encephalitis virus NS5 associates with membrane protein scribble and impairs interferon-stimulated JAK-STAT signalling." Werme K., Wigerius M., Johansson M. Cell. Microbiol. 10:696-712(2008) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH TICK-BORNE ENCEPHALITIS VIRUS RNA-DIRECTED RNA POLYMERASE NS5. |
| [24] | "A quantitative atlas of mitotic phosphorylation." Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., Elledge S.J., Gygi S.P. Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-826; SER-939; SER-1223; SER-1232; SER-1306; SER-1309; THR-1342; SER-1348; SER-1437; SER-1547 AND SER-1566, MASS SPECTROMETRY. Tissue: Cervix carcinoma. |
| [25] | "MCC, a new interacting protein for Scrib, is required for cell migration in epithelial cells." Arnaud C., Sebbagh M., Nola S., Audebert S., Bidaut G., Hermant A., Gayet O., Dusetti N.J., Ollendorff V., Santoni M.J., Borg J.P., Lecine P. FEBS Lett. 583:2326-2332(2009) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH MCC. |
| [26] | "Large-scale proteomics analysis of the human kinome." Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., Mann M., Daub H. Mol. Cell. Proteomics 8:1751-1764(2009) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1348 AND SER-1448, MASS SPECTROMETRY. |
| [27] | "Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions." Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., Rodionov V., Han D.K. Sci. Signal. 2:RA46-RA46(2009) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-826; SER-1220; THR-1342; SER-1348; SER-1475; SER-1547 AND SER-1566, MASS SPECTROMETRY. Tissue: Leukemic T-cell. |
| [28] | "Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis." Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M. Sci. Signal. 3:RA3-RA3(2010) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-826; SER-835; SER-853; SER-939; SER-1140; SER-1220; SER-1232; THR-1342; SER-1348; SER-1378; SER-1448; SER-1475; SER-1486 AND SER-1566, MASS SPECTROMETRY. Tissue: Cervix carcinoma. |
| [29] | "Initial characterization of the human central proteome." Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J. BMC Syst. Biol. 5:17-17(2011) [PubMed] [Europe PMC] [Abstract] Cited for: IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. |
| [30] | "System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation." Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B. Sci. Signal. 4:RS3-RS3(2011) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-688; THR-689; SER-1220; SER-1309; SER-1378 AND SER-1448, MASS SPECTROMETRY. |
| [31] | "Solution structure of the first, second and fourth PDZ domain of human scribble (KIAA0147 protein)." RIKEN structural genomics initiative (RSGI) Submitted (NOV-2005) to the PDB data bank Cited for: STRUCTURE BY NMR OF 718-814; 860-951 AND 1096-1193. |
| [32] | "Mutations in the planar cell polarity genes CELSR1 and SCRIB are associated with the severe neural tube defect craniorachischisis." Robinson A., Escuin S., Doudney K., Vekemans M., Stevenson R.E., Greene N.D., Copp A.J., Stanier P. Hum. Mutat. 33:440-447(2012) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS NTD SER-454 AND GLN-1535, CHARACTERIZATION OF VARIANTS NTD SER-454 AND GLN-1535. |
| + | Additional computationally mapped references. |
Cross-references
Sequence databases | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EMBL GenBank DDBJ | AF240677 mRNA. Translation: AAP88017.1. AY062238 mRNA. Translation: AAL38976.1. AF271734 mRNA. Translation: AAP88018.2. D63481 mRNA. Translation: BAA09768.3. AC105219 Genomic DNA. No translation available. BC009490 mRNA. Translation: AAH09490.2. BC014632 mRNA. Translation: AAH14632.2. | ||||||||||||||||||||||||||||||
| IPI | IPI00410666. IPI00425560. IPI00425562. | ||||||||||||||||||||||||||||||
| RefSeq | NP_056171.3. NM_015356.4. NP_874365.3. NM_182706.4. | ||||||||||||||||||||||||||||||
| UniGene | Hs.436329. | ||||||||||||||||||||||||||||||
3D structure databases | |||||||||||||||||||||||||||||||
| PDBe RCSB PDB PDBj |
| ||||||||||||||||||||||||||||||
| ProteinModelPortal | Q14160. | ||||||||||||||||||||||||||||||
| ModBase | Search... | ||||||||||||||||||||||||||||||
Protein-protein interaction databases | |||||||||||||||||||||||||||||||
| DIP | DIP-31259N. | ||||||||||||||||||||||||||||||
| IntAct | Q14160. 16 interactions. | ||||||||||||||||||||||||||||||
| MINT | MINT-147371. | ||||||||||||||||||||||||||||||
| STRING | 9606.ENSP00000349486. | ||||||||||||||||||||||||||||||
PTM databases | |||||||||||||||||||||||||||||||
| PhosphoSite | Q14160. | ||||||||||||||||||||||||||||||
Polymorphism databases | |||||||||||||||||||||||||||||||
| DMDM | 261260101. | ||||||||||||||||||||||||||||||
Proteomic databases | |||||||||||||||||||||||||||||||
| PaxDb | Q14160. | ||||||||||||||||||||||||||||||
| PRIDE | Q14160. | ||||||||||||||||||||||||||||||
Protocols and materials databases | |||||||||||||||||||||||||||||||
| DNASU | 23513. | ||||||||||||||||||||||||||||||
| StructuralBiologyKnowledgebase | Search... | ||||||||||||||||||||||||||||||
Genome annotation databases | |||||||||||||||||||||||||||||||
| Ensembl | ENST00000320476; ENSP00000322938; ENSG00000180900. ENST00000356994; ENSP00000349486; ENSG00000180900. ENST00000377533; ENSP00000366756; ENSG00000180900. ENST00000564122; ENSP00000456859; ENSG00000260968. ENST00000567584; ENSP00000456561; ENSG00000260968. ENST00000569114; ENSP00000455629; ENSG00000260968. | ||||||||||||||||||||||||||||||
| GeneID | 23513. | ||||||||||||||||||||||||||||||
| KEGG | hsa:23513. | ||||||||||||||||||||||||||||||
| UCSC | uc003yzo.1. human. uc003yzp.1. human. | ||||||||||||||||||||||||||||||
Organism-specific databases | |||||||||||||||||||||||||||||||
| CTD | 23513. | ||||||||||||||||||||||||||||||
| GeneCards | GC08M144874. | ||||||||||||||||||||||||||||||
| HGNC | HGNC:30377. SCRIB. | ||||||||||||||||||||||||||||||
| HPA | CAB015463. CAB022081. HPA023557. | ||||||||||||||||||||||||||||||
| MIM | 182940. phenotype. 607733. gene. | ||||||||||||||||||||||||||||||
| neXtProt | NX_Q14160. | ||||||||||||||||||||||||||||||
| PharmGKB | PA134936275. | ||||||||||||||||||||||||||||||
| HUGE | Search... | ||||||||||||||||||||||||||||||
| GenAtlas | Search... | ||||||||||||||||||||||||||||||
Phylogenomic databases | |||||||||||||||||||||||||||||||
| eggNOG | COG4886. | ||||||||||||||||||||||||||||||
| HOGENOM | HOG000113281. | ||||||||||||||||||||||||||||||
| KO | K16175. | ||||||||||||||||||||||||||||||
| OMA | GHRNSLE. | ||||||||||||||||||||||||||||||
Gene expression databases | |||||||||||||||||||||||||||||||
| ArrayExpress | Q14160. | ||||||||||||||||||||||||||||||
| Bgee | Q14160. | ||||||||||||||||||||||||||||||
| CleanEx | HS_SCRIB. | ||||||||||||||||||||||||||||||
| Genevestigator | Q14160. | ||||||||||||||||||||||||||||||
| GermOnline | ENSG00000180900. Homo sapiens. | ||||||||||||||||||||||||||||||
Family and domain databases | |||||||||||||||||||||||||||||||
| InterPro | IPR001611. Leu-rich_rpt. IPR025875. Leu-rich_rpt_4. IPR003591. Leu-rich_rpt_typical-subtyp. IPR001478. PDZ. [Graphical view] | ||||||||||||||||||||||||||||||
| Pfam | PF12799. LRR_4. 2 hits. PF00595. PDZ. 4 hits. [Graphical view] | ||||||||||||||||||||||||||||||
| SMART | SM00369. LRR_TYP. 2 hits. SM00228. PDZ. 4 hits. [Graphical view] | ||||||||||||||||||||||||||||||
| SUPFAM | SSF50156. PDZ. 4 hits. | ||||||||||||||||||||||||||||||
| PROSITE | PS51450. LRR. 13 hits. PS50106. PDZ. 4 hits. [Graphical view] | ||||||||||||||||||||||||||||||
| ProtoNet | Search... | ||||||||||||||||||||||||||||||
Other | |||||||||||||||||||||||||||||||
| EvolutionaryTrace | Q14160. | ||||||||||||||||||||||||||||||
| GenomeRNAi | 23513. | ||||||||||||||||||||||||||||||
| NextBio | 45935. | ||||||||||||||||||||||||||||||
| SOURCE | Search... | ||||||||||||||||||||||||||||||
Entry information
| Entry name | SCRIB_HUMAN | ||||||||
| Accession | Primary (citable) accession number: Q14160 Secondary accession number(s): Q6P496 Q96GG1 | ||||||||
| Entry history |
| ||||||||
| Entry status | Reviewed (UniProtKB/Swiss-Prot) | ||||||||
| Annotation program | Chordata Protein Annotation Program | ||||||||
| Disclaimer | Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. It is not in any way intended to be used as a substitute for professional medical advice, diagnosis, treatment or care. | ||||||||
Relevant documents
| Human chromosome 8 Human chromosome 8: entries, gene names and cross-references to MIM |
| Human entries with polymorphisms or disease mutations List of human entries with polymorphisms or disease mutations |
| Human polymorphisms and disease mutations Index of human polymorphisms and disease mutations |
| MIM cross-references Online Mendelian Inheritance in Man (MIM) cross-references in UniProtKB/Swiss-Prot |
| PDB cross-references Index of Protein Data Bank (PDB) cross-references |
| SIMILARITY comments Index of protein domains and families |

Clusters with
